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Abstract 
Background 
Few cancers pose greater challenges than head and neck (H&N) cancer. Residual effects 
following treatment include body image changes, pain, fatigue and difficulties with appetite, 
swallowing and speech. Depression is a common comorbidity. There is limited evidence 
about ways to assist patients to achieve optimal adjustment after completion of treatment. In 
this study, we aim to examine the effectiveness and feasibility of a model of survivorship care 
to improve the quality of life of patients who have completed treatment for H&N cancer. 
Methods/Design 
This is a preliminary study in which 120 patients will be recruited. A prospective randomised 
controlled trial of the H&N Cancer Survivor Self-management Care Plan (HNCP) involving 
pre- and post-intervention assessments will be used. Consecutive patients who have 
completed a defined treatment protocol for H&N cancer will be recruited from two large 
cancer services and randomly allocated to one of three study arms: (1) usual care, (2) 
information in the form of a written resource or (3) the HNCP delivered by an oncology nurse 
who has participated in manual-based training and skill development in patient self-
management support. The trained nurses will meet patients in a face-to-face interview lasting 
up to 60 minutes to develop an individualised HNCP, based on principles of chronic disease 
self-management. Participants will be assessed at baseline, 3 and 6 months. The primary 
outcome measure is quality of life. The secondary outcome measures include mood, self-
efficacy and health-care utilisation. The feasibility of implementing this intervention in 
routine clinical care will be assessed through semistructured interviews with participating 
nurses, managers and administrators. Interviews with patients who received the HNCP will 
explore their perceptions of the HNCP, including factors that assisted them in achieving 
behavioural change. 
Discussion 
In this study, we aim to improve the quality of life of a patient population with unique needs 
by means of a tailored self-management care plan developed upon completion of treatment. 
Delivery of the intervention by trained oncology nurses is likely to be acceptable to patients 
and, if successful, will be a model of care that can be implemented for diverse patient 
populations. 
Trial registration 
ACTRN12613000542796 (registered on 15 May 2013) 
Keywords 
Head and neck cancer, Self-management, Survivorship 
Background 
Historically, the diagnosis of cancer was feared because of the perception that it inevitably 
led to death. Now, owing to a combination of early detection and improved treatments, death 
rates due to cancer in the United States and other developed countries continue to fall [1]. 
However, these falling death rates, combined with an ageing population, mean that there are 
increasing numbers of cancer survivors who must adjust to their diagnoses, residual 
symptoms and side effects of treatment [2]. Many who have survived cancer report positive 
changes in their lives; however, resentment is also experienced, especially amongst those 
with physical deformities, health problems resulting from cancer and its treatment, residual 
pain and social isolation. All of these factors can adversely affect quality of life (QoL) more 
than 15 years beyond the initial diagnosis [3]. Despite these burdens, at a systems level, there 
remain gaps in survivorship care [4]. In many settings, there is not a comprehensive approach 
to the needs of cancer survivors, with follow-up focusing on surveillance rather than health 
promotion. 
Among all cancers, few pose more challenges for survivors than head and neck (H&N) 
cancers. H&N cancers include cancers of the tongue; mouth; salivary glands; pharynx; oro-, 
hypo- and nasopharynx; nasal cavities; middle ear; sinuses; and larynx. Treatments can 
involve extensive surgery, which may result in marked disfigurement, especially if treatments 
include extensive neck dissection or removal of part of the maxilla or mandible. Some 
patients require exenteration of an eye, which has obvious implications for their self-esteem, 
functional ability and social relationships. It is unsurprising, then, that up to 75% of H&N 
cancer patients treated surgically have body image concerns [5]. In addition, the toxicities of 
concurrent chemotherapy and radiotherapy, which include haematological toxicity, 
desquamation, mucositis, pain, dysphagia and trismus, lead to delays in treatment in almost 
half of these patients [6]. Even after completion of treatment, these patients struggle with 
residual problems, such as reduced shoulder movement and shoulder and neck pain, all of 
which adversely affect their QoL [7]. 
Authors of a recent review reported that residual concerns at 12 months following completion 
of treatment included deterioration in physical functioning, xerostomia and sticky saliva [8]. 
Difficulty with saliva and swallowing can lead to concerns about social eating [9]. This has 
the potential to decrease social activities and erode relationships, which are predictive of 
anxiety in cancer survivors [10,11]. Fatigue further affects one-third of patients 12 months 
after completion of treatment, whilst appetite loss affects 36% [12]. Thus it is unsurprising 
that 35% of patients with H&N cancer experience clinical depression [13]. Pain, fatigue and 
depression persist in many patients [10], indicating the need for preemptive interventions 
rather than expectant watchfulness. Highlighting the iterative nature of these psychosocial 
issues is that heavy alcohol use, which is a risk factor for the development of H&N cancer 
[14], has been reported in up to one-third of patients with H&N cancer [15]. Stigma regarding 
disfigurement and guilt about one’s possible personal contribution towards the development 
of the cancer (through alcohol abuse or smoking) also adversely affect psychosocial 
adjustment [16]. 
The emergence of a new patient population with H&N cancer, those affected by human 
papillomavirus (HPV), is of particular concern. These patients are often younger, which is a 
risk factor for increased psychosocial distress [17]. However, to date, there has been a paucity 
of research examining the psychosocial impact of cancer in this population. Studies in which 
researchers have explored stigma about HPV have been confined to the association with 
cervical cancer and have revealed a greater level of stigma for males than for females [18]. 
Research in which investigators have assessed interventions to assist patients in coping with 
the stigma related to HPV in general is limited, although preliminary evidence suggests that 
educational messages may alter perceptions [19]. This patient population is highly vulnerable 
because of their younger age, the lack of research designed to define their specific needs and 
the absence of evidence to guide optimal interventions to promote adjustment. 
Interventions to assist head and neck cancer survivors 
Given the complex, ongoing problems experienced by patients treated for H&N cancer, 
supportive interventions are vital for this population. However, compared with cancers such 
as breast and prostate cancer, H&N cancer has not received widespread attention, nor have 
H&N cancer patients had ready access to tailored psychosocial interventions or support 
groups. The authors of a review of interventions designed specifically for H&N cancer 
patients described some evidence of benefit due to psychoeducational initiatives [20]; 
however, few robust studies in this population have been conducted to date. In the United 
Kingdom, pilot testing of a psychoeducational intervention for patients during treatment 
demonstrated improvement in patient knowledge and body image [21]. Improvements in 
mood and QoL were also achieved through a psychoeducational intervention in one trial [22]; 
however, the trial was not randomised. Widespread implementation of the type of 
intervention used in that trial is likely to be limited by its therapist-intensive nature, as it 
requires four sessions, each lasting 90 minutes. 
Our team developed a resource for patients who had completed treatment for H&N cancer. 
The resource, “Facing the Future: Living with Confidence after Treatment for Head and Neck 
Cancer,” is based on evidence about issues concerning patients treated for H&N cancer. 
These issues include physical changes, work, day-to-day tasks, interpersonal relationships 
and social functioning [23]. Members of the Royal Brisbane and Women’s Hospital (RBWH) 
multidisciplinary Ambulatory Care Enhancement Team (ACET) collaborated to provide 
information and practical recommendations about strategies patients could use to respond to 
these and other problems. An initial draft of the resource was prepared and critically 
reviewed by members of a local H&N cancer support group. Consumer feedback was 
incorporated into the draft, and the resource was further refined before a second round of 
consultation with members of the H&N cancer support group and the ACET team, after 
which the final version was prepared. 
The 61-page resource guide was pilot-tested from late 2011 through early 2012 with 18 
patients who had completed treatment for H&N cancer at RBWH. The positive endorsement 
of the content and information contained in the resource did not translate to reported changes 
in behaviour or levels or confidence. Only 39% of respondents said that having this resource 
would increase their confidence about coping after treatment “a lot”, and 39% said it would 
increase their confidence about coping either “not at all” or “a little”. Furthermore, no 
respondents indicated that they had made “a lot” or “an extreme amount” of change in their 
routines or had started new activities since reading the guide, and 22% had made “a fair bit” 
of change. The remainder had made only a little change, and 22% had made no changes at all. 
These pilot data highlight the limited impact of the provision of information alone in 
facilitating behavioural changes that have the potential to improve H&N patients’ QoL. 
In contrast, emerging evidence from the field of chronic disease management demonstrates 
that an active collaborative approach to problem definition, in conjunction with the 
development of self-management strategies, leads to improved coping with symptoms 
[24,25]. In a pilot study of patients who had completed treatment for breast and colorectal 
cancer, Yates et al. [26] utilised this chronic disease self-management approach to develop a 
survivorship care plan focused on developing patients’ self-management capacity. There 
were significant differences between the control and intervention groups between the baseline 
and 6-month follow-up assessments. Compared with the control group, patients who received 
the self-management intervention had significantly greater improvement over time in their 
functional well-being and self-efficacy in maintaining relationships. 
Rationale for this study 
The development of evidence-based models of cancer survivorship care remains important, 
especially for disadvantaged or marginalised patient populations [27]. In this study, we aim to 
improve the QoL of patients treated for H&N cancer through the H&N Cancer Survivor Self-
management Care Plan (HNCP), which is based on the model for survivorship care plans 
advocated by the US Institute of Medicine [4] and informed by the principles contained in the 
chronic condition and self-management model published by the Australian Government 
Department of Health and Ageing [24,25]. Not a generic intervention, the will be an 
individualised management plan for each patient, in line with emerging evidence about the 
benefits of a prioritised care plan [28] that is explicitly aligned with the needs of individual 
patients [29]. 
Promotion of self-efficacy [30] is the fundamental theoretical platform of this intervention. 
Self-efficacy refers to an individual’s beliefs regarding his or her capacity to respond to 
challenges. Self-efficacy is postulated to predict (1) whether the individual will initiate a 
response to challenges, (2) how hard the patient will work at those challenges and (3) the 
extent to which the patient will persist despite adversity or setbacks. This model is ideally 
suited to developing self-management behaviours in patients treated for H&N cancer because 
the constellation of residual symptoms they experience may feel overwhelming, thereby 
undermining (1) their optimism about improving their health and (2) their beliefs about their 
ability to implement self-care actions that can effectively address their health concerns. An 
intervention targeting self-efficacy is likely to lead to sustained improvements in self-
management of ongoing health concerns, with the improvements lasting beyond the duration 
of the intervention. Table 1 lists strategies that are used to promote self-efficacy. 
Table 1 Techniques designed to promote self-efficacy 
Techniques Methods 
Performance 
accomplishment 
In this study, participants will be assisted to achieve incremental mastery 
over manageable tasks, which could in turn increase their willingness to 
engage in other self-care behaviours. 
Vicarious 
experience 
Participants in this study will observe the nurse modelling skills so that 
the can learn the steps required to complete a specific task. 
Verbal persuasion The nurse will build the patient’s confidence and provide encouragement, 
as there is evidence that people who are persuaded that they possess the 
requisite skills to master a challenge are more likely to apply greater 
effort than those who receive information alone, especially if the 
information comes from a credible source. 
Attention to 
physiological 
states 
Anxiety affects patients’ attitudes about their ability to deal with 
problems and reduces performance, so relaxation and other techniques 
will be used to reduce physiological arousal. 
Methods/Design 
Study aims and hypotheses 
Our primary aim in this study is to evaluate the effectiveness of a focused intervention (the 
HNCP) in improving the QoL of H&N cancer survivors. The HNCP will be developed for 
each patient in collaboration with an oncology nurse who has participated in focused training 
in developing an individual’s self-management capacity and will receive clinical supervision 
during the delivery of the intervention. 
Our secondary aims in the study are to evaluate (1) the impact of the HNCP on patient self-
efficacy, mood and ability to engage in self-management behaviours that promote optimal 
health and well-being, (2) the cost impact on the health system of using this model of care in 
routine clinical practice and (3) the feasibility of integration of the HNCP into routine clinical 
practice, including identification of systems and patient barriers through interviews with 
participating nurses, nursing and medical directors of clinics, and patients. 
We hypothesise that (1) at 6 months following the intervention, patients who receive the 
HNCP will have significantly improved QoL compared with patients who do not receive the 
HNCP, (2) the HNCP will be highly acceptable to patients and (3) at 6 months following the 
intervention, patients who receive the HNCP will be using significantly fewer health-care 
resources than patients who do not receive the HNCP. 
Interventions 
The study design is a prospective randomised controlled trial (RCT) of the HNCP 
intervention using pre- and postintervention assessments. The study will be conducted in the 
cancer services of two large tertiary referral centres that provide multidisciplinary care for 
patients with H&N cancer. Oncology nurses at both centres will be recruited to participate in 
focused training in order to be able to deliver the HNCP. Once a sufficient number of nurses 
are trained (approximately 15 nurses in total patients will be recruited. The central project 
manager will use a computer-generated list of random numbers to allocate recruited patients 
to one of the three study arms that are described in the subsections below. 
Usual care 
Patients in the usual care arm will continue to receive standard care and other usual 
supportive care measures, including medical treatments and health-care appointments. These 
patients will not have contact with the trained nurses other than in the course of routine 
clinical care. 
Information only 
In addition to usual care, patients in this group will receive a copy of “Facing the Future: 
Living with Confidence after Treatment for Head and Neck Cancer.” The central project 
manager will forward copies of this resource guide directly to patients randomised to this arm 
of the study. These patients will not have contact with the trained nurses other than in the 
course of routine clinical care. 
Intervention 
Each patient randomised to the intervention arm of the study will receive an individualised 
HNCP within 1 month of completion of treatment. The HNCP will be developed during a 
face-to-face supportive and educational session between the patient and a trained nurse. The 
session will last up to 60 minutes and will be focused on developing the patient’s self-
efficacy to manage identified health concerns. During the consultation, the patient and nurse 
will collaborate to define problems of concern to the patient and develop strategies targeted to 
address these concerns through practical goal-setting and planning. Information will be 
provided about symptom management, and strategies to promote behaviour change will also 
be discussed (for example, in relation to smoking). The HNCP will define follow-up and 
engagement with health-care systems and sources of community and social support [31]. 
Patients will also receive a copy of the resource “Facing the Future: Living with Confidence 
after Treatment for Head and Neck Cancer” and continue to receive usual care. To facilitate 
consistent, ongoing support, a copy of the HNCP will be sent to the patient’s general 
practitioner. A summary of the three study arms is presented in Table 2. 
Table 2 Differences in conditions between the three arms of this study 
 Study conditions 
Study arms Individualised H&N 
Cancer Survivorship 
Self- Management Care 
Plan (HNCP) 
Receive a copy of the 
resource “Facing the Future: 
Living with Confidence after 
Treatment for Head and 
Neck Cancer” 
Continue to receive standard care 
and other usual supportive care 
measures, including medical 
treatments and health-care 
appointments 
HNCP 
(intervention) 
√ √ √ 
Information * √ √ 
Usual care * * √ 
√ Intervention component implemented. 
* Intervention component not implemented. 
Participants 
Oncology nurses 
Oncology nurses currently working at either cancer service will be eligible to participate if 
they (1) are registered nurses, (2) have at least 12 months of clinical experience in oncology, 
(3) are currently engaged in patient contact for at least 6 hours per week, (4) can commit to 
undertake the necessary training and (5) work in a setting in which they can deliver the 
intervention (that is, the HNCP). Those nurses who anticipate leaving their current work 
setting within the next 12 months or taking a period of extended leave during the conduct of 
the study will not be eligible to participate. Informed consent will be obtained from all nurses 
recruited to participate in the study. 
The recruited oncology nurses will undergo extensive manual-based training to develop 
advanced knowledge and skills in developing individualised self-management care plans for 
patients, specifically with respect to the following core concepts: (1) health promotion 
approaches, (2) assessment of health risk factors, (3) communication skills, (4) assessment of 
self-management capacity, (5) collaborative care planning, (6) use of peer support, cultural 
awareness, (7) psychosocial assessment and support, (8) motivational interviewing, (9) 
collaborative problem definition, (10) goal-setting, (11) action planning and (12) structured 
problem-solving [24]. After they have worked through the training manual, the nurses will 
participate in skill development conducted face-to-face by JT, PY and ALM. Decision 
support tools will provide a framework for the nurses to tailor the HNCP to the specific needs 
of each patient, and, whilst delivering the intervention, the nurses will participate in 
fortnightly clinical supervision. Clinical supervision will be conducted in a group format 
facilitated by JT, PY and ALM, who have extensive experience in supervision. During the 
supervision sessions, participating nurses will present an overview of the HNCPs that they 
have developed and will be assisted to devise strategies for responding to any challenges they 
experience. We aim to train 15 oncology nurses so that all will have the opportunity to 
deliver the HNCP on several occasions, but without posing a burden in terms of their routine 
clinical roles. 
Patients 
The patients eligible for this study must have received treatment for H&N cancer at one of 
the two cancer services. The inclusion criteria are (1) age 18 years or older; (2) completion of 
a defined treatment protocol for cancer of the tongue; mouth; salivary glands; pharynx; oro-, 
hypo- nd/or nasopharynx; nasal cavities; middle ear; sinuses; or larynx or completion of a 
defined treatment protocol for nonmelanoma skin cancers of the head and neck requiring 
treatment known to cause toxicity (for example, any one or combination of surgery, 
radiotherapy or chemotherapy); and (3) possess physical, cognitive and mental status 
enabling participation in the study. Exclusion criteria are (1) inability to speak and read 
English; (2) currently receiving low-toxicity treatment for H&N cancer (for example, laser 
therapy alone); (3) the presence of severe mental, cognitive or physical conditions that would 
limit the patient’s ability to participate in the study or that require regular ongoing specialist 
treatment; and (4) advanced disease if life expectancy is expected to be less than 6 months. 
Informed consent to participate will be obtained from all patients recruited into the study. 
There is insufficient evidence from other RCTs on which to base calculation of an adequate 
sample size for assessing a psychosocial intervention for H&N cancer patients. There are also 
limited published data about meaningful changes in scores on the Functional Assessment of 
Cancer Therapy–Head and Neck (FACT–H&N) [32], although this QoL instrument is 
deemed the most appropriate measurement tool for capturing the unique concerns of patients 
with H&N cancer [33]. Hence, for this preliminary study, the sample size of 40 patients per 
group (a total of 120 patients) is based on our capacity to enrol and retain patients, and to 
conduct the interventions and follow-up, within the time frame for which the study is funded 
[34]. This study is not powered for hypothesis testing, but it will allow us to determine which 
changes in the QoL measurement are meaningful to patients and will assist us in calculating 
the sample size for a subsequent, larger, multisite RCT in which a formal economic cost-
effectiveness study can be included. 
Clinical directors and managers 
We will provide information about the study to clinical directors and managers at baseline 
and aim to recruit all relevant managers at each site for interviews to be conducted upon 
completion of the study. 
Study integrity 
Multisite ethical approval for both sites involved in recruitment of participants into this study 
has been obtained from the Human Research Ethics Committee of RBWH 
(HREC/13/QRBW/94, dated 24 April 2013), and administrative ethical approval has been 
obtained from the human research ethics committees of the University of Queensland 
(Medical Research Ethics Committee approval 2013000654, dated 24 May 2013) and the 
Queensland University of Technology (approval 1300000640, dated 11 October 2013). The 
study will be conducted in accordance with the ethical standards of the responsible 
institutional human ethics committees and the Declaration of Helsinki (1983 revision). The 
study will be conducted in adherence to the CONSORT (Consolidated Standards of 
Reporting Trials) statement on randomised trials [35] and will be carried out concurrently at 
the two cancer services. Every consecutive patient attending the outpatient H&N cancer 
clinic at each cancer service will be screened for eligibility by a trained research assistant and 
enrolled if eligible and consenting. Careful documentation of outpatient attendance, 
subsequent enrolments and consent interviews will ensure that no patient is “selected” for 
inclusion or exclusion from the study. 
The central project manager will allocate patients to one of the three study arms using a 
computer-generated list of random numbers. The manager will notify trained nurses, who will 
then contact those patients who have been randomised to receive the intervention. Fidelity to 
the treatment protocol will be ensured through rigorous training of nurses by means of a 
standardised manual, and skills development will be facilitated by JT, PY and ALM. In 
addition, nurses will participate in fortnightly supervision whilst delivering the interventions. 
At least one session conducted by a nurse each month will be audio-recorded to assess 
compliance with the study protocol and to provide feedback to the nurse. The central project 
manager or his or her delegate will forward copies of the resource guide “Facing the Future: 
Living with Confidence after Treatment for Head and Neck Cancer” directly to patients 
randomised to the information-only arm of the study. 
Research staff involved in pre- and postintervention assessments will be blinded to the 
allocation status of the patient, as will clinical staff. If group allocation is inadvertently 
revealed to research staff by patients during follow-up assessments, this information will be 
recorded and analysis will be undertaken to assess for any effects. 
No participating oncology nurses will be randomised. All will receive the training and will 
have an opportunity to deliver the HNCP to patients who have been randomised to receive 
the intervention. 
Measures 
Oncology nurses 
At recruitment, participating nurses will be asked to provide demographic information and 
details regarding their clinical experience and specific training in psychooncology. Upon 
conclusion of the study, the nurses will be asked to participate in a semistructured interview 
designed to elicit their perceptions of participation in the study as well as enablers and 
barriers to implementation of this model of care in routine clinical practice. 
Patient measures 
Patient measures will be completed at baseline and at 3-month and 6-month follow-up 
appointments. 
Clinical and demographic characteristics 
At baseline, structured templates will be used to record age, marital status, education, tumour 
site, location and extent of metastases and anticancer and supportive therapies. Changes in 
clinical status and subsequent receipt of any anticancer treatment (surgery, chemotherapy 
and/or radiotherapy) and supportive treatments will be recorded at other time points to enable 
comparison of the intervention (the HNCP) with the information-only and usual-care groups 
on key clinical and treatment variables that may influence the effectiveness of the 
intervention or the outcomes of interest in this study. 
Primary outcome 
QoL will be assessed using the FACT–H&N instrument [33]. The original FACT–General 
was developed and validated more than 10 years ago [36] and has been used in hundreds of 
studies worldwide. It is a self-report instrument consisting of 27 core items designed to assess 
function in 4 domains: (1) physical well-being, (2) social/family, (3) emotional well-being 
and (4) functional well-being. The FACT–H&N instrument includes an additional 12 items 
used to assess H&N cancer–related symptoms, which capture the unique concerns of this 
patient population that are not obtained with more generic measures [33]. It has been 
demonstrated to be a reliable and valid measure in this patient population [37]. Items are 
rated on a 0 to 4 Likert scale, then combined to produce subscale scores for each domain as 
well as a global QoL score. 
Secondary outcomes 
Self-efficacy 
The Cancer Behaviour Inventory version 2.0 [38] is a measure of self-efficacy for coping 
with cancer and includes a stress management scale. It consists of 33 items that are used to 
measure function in seven domains: (1) maintaining activity and independence, (2) seeking 
and understanding medical information, (3) managing stress, (4) coping with treatment-
related side effects, (5) accepting cancer and maintaining a positive attitude, (6) regulating 
affect and (7) seeking support. This instrument is considered to be reliable and valid as well 
as sensitive to change over time [38]. 
Mood 
The Hospital Anxiety and Depression Scale [39] is a 14-item scale that has good reliability 
and validity. It has been used extensively in studies of cancer patients. Cutoff scores of 22 
and above represent severe disorder, and scores less than 8 represent no disorder. 
Generic quality of life 
The European Quality of Life Questionnaire (EuroQol) 5-level version (EQ-5D) [40] is a 
preference-based utility instrument that will be used for the economic analysis. The EQ-5D 
has five dimensions covering multiple aspects of QoL. It is a validated and reliable tool for 
utility measurement in economic studies. An algorithm has recently been developed for 
Australian populations within economic studies in Australia [41]. 
Process measures 
At the conclusion of the study, nurses will be asked a structured series of questions designed 
to assess perceived enablers and barriers to delivery of the HNCP in clinical practice. Similar 
information will be obtained from medical and nursing directors at the clinics. In addition, 
upon the completion of the intervention, patients in the intervention group will be asked to 
respond to a series of questions related to their perceptions of the effectiveness of the 
intervention sessions and their satisfaction with them. They will also be asked about factors 
that facilitated or impeded their ability to participate in the intervention and initiate behaviour 
changes. 
Economic study 
The economic study will be undertaken from a health-care provider’s perspective (public and 
private hospitals) and will involve assessment of (1) intervention resources by identifying, 
quantifying and valuing resources using standard methods [42] and (2) utilisation and cost of 
doctor visits and medications for all participants over the course of a 12-month period 
covering 3 months preintervention, 6 months during the intervention and 3 months 
postintervention completion. 
Investigators will maintain detailed records of direct costs of delivering the intervention 
(staffing, training, telephone costs, office consumables and printing and production of 
educational materials) for the duration of the study. Resources will be valued using 
standardised national fee schedules, salary schedules for personnel and retail prices for other 
general consumables. To test the occurrence of the medical offset effect as a benefit of the 
intervention, administrative data on doctor visits and medications will be requested from 
Medicare Australia records. 
Statistical analyses 
Analyses will be conducted using IBM SPSS version 21 software (IBM SPSS, Chicago, IL, 
USA). Descriptive statistics of patients’ demographic and clinical characteristics at baseline 
will be generated for each treatment group for the purpose of considering the success of the 
randomisation. Summary measures at time 1 (baseline), time 2 (3-month follow-up) and time 
3 (6-month follow-up) will be calculated as means for continuous variables and as 
proportions for categorical measures, including 95% confidence intervals. Separate analyses 
will be conducted for each outcome variable. For continuous variables, the difference 
between groups in the change in mean scores over time will be evaluated using a generalized 
linear mixed effects model with all available data controlled for the potential cluster effect of 
different sites. Otherwise, logistic regression analysis will be conducted. A group-by-time 
interaction effect will be included in all models. All analyses will be conducted on an 
intention-to-treat basis. 
Qualitative data 
Audio-recorded intervention sessions will be transcribed, and content will be analysed (1) to 
document the frequency with which various strategies were used by nurses and the perceived 
effectiveness and satisfaction with the strategies and (2) to identify common themes that 
reflect issues impacting the intervention, including situational, patient-related, nurse-related 
or intervention-related factors. This analysis will provide useful information regarding 
intervention processes whilst also enabling assessment of adherence to the intervention 
protocol. 
Economic analyses 
Intervention resource costs will be aggregated across the groups to assess the incremental 
cost differences. We will also explore the incremental health benefits of the intervention 
(each of the arms separately) over and above what occurs with usual care as measured by the 
EQ-5D scores for suitability within a potential cost-effectiveness analysis. Medicare data on 
doctor visits and medication use (type, quantity and associated cost) will be analysed to 
obtain means and 95% confidence intervals using bootstrapping statistics [43] to account for 
the expected rightward-skewing nature of health-care resource use. Bootstrapped mean 
differences in health-care utilisation across the three groups will be assessed using Wald tests 
and calculated using Stata/SE 12 software (StataCorp, College Station, TX, USA). 
Discussion 
Despite increasing acknowledgement of the needs of cancer survivors, many cancer services 
still do not offer focused interventions to promote their well-being. Currently, there is a 
paucity of research demonstrating effective models of survivorship care that are feasible to 
deliver in busy clinical services, which are often resource-poor. 
This study is the first of its kind in Australia. It targets a patient population that faces the 
additive challenges of intensive treatments and severe side effects, often against a 
background of premorbid vulnerability. Despite documented high levels of depression, the 
lack of a political voice and advocacy has seen the needs of this cancer population neglected 
relative to those of patients with other cancers, such as breast cancer or, increasingly, prostate 
cancer. 
Embedding the intervention into clinical care is likely not only to be acceptable to patients 
[44] but also to address the barriers of stigma and the burden of travel to receive assistance 
[45-47], because the intervention can be delivered to patients in rural and remote areas by 
appropriately trained local nurses. Furthermore, it has been proposed that supportive care 
interventions for people with cancer will produce downstream economic benefits in the form 
of reduced use of physicians’ services and medications due to the intervention’s successfully 
meeting the specific needs of patients [48]. However, as yet, there is no firm evidence to 
support this medical “cost-offset effect”. 
If successful, this study will (1) provide evidence about a model of care structured to improve 
QoL in a cancer patient population with unique and complex needs, (2) add to the evidence 
base with respect to chronic disease self-management interventions and (3) provide a basis 
for a larger multisite study designed to examine the feasibility and cost-effectiveness of this 
comprehensive survivorship intervention in different treatment settings. 
Trial status 
Fifteen oncology nurses have been recruited and completed training in order to be able to 
deliver the intervention. Eight patients have been recruited across both sites to date. 
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